MilliporeSigma Launches Next-Gen Process Technologies


Three new products aim to improve speed and cost efficiency

MilliporeSigma has launched three new products for biomanufacturers. The Eshmuno CP-FT resin, a first-of-its kind CEX chromatography resin for the flow-through removal of aggregates from mAb therapeutics; two modified amino acids to simplify feeding and reduce total volume in cell culture: Phospho-L-Tyrosine Disodium Salt EMPROVE EXPERTand L-Cysteine S-Sulfate Sodium Sesquihydrate EMPROVE EXPERT.
“MilliporeSigma is uniquely qualified to lead the industry through the next-generation evolution and down the path of process intensification,” said Udit Batra, chief executive officer, MilliporeSigma. “Through these next-generation process intensification technologies, we are helping customers bring new therapies to market, delivering them to patients faster and more cost-effectively than ever before.”
The Eshmuno CP-FT CEX chromatography resin uses flow-through frontal chromatography to remove aggregates from mAb therapeutics, which can induce an immunogenic response in patients. According to the company, by enabling loading capacities 10 times higher than traditional bind/elute CEX chromatography, Eshmuno CP-FT resin reduces costs and improves productivity. It requires less resin and less buffer volume while offering a shorter processing time.
Phospho-L-Tyrosine Disodium Salt EMPROVE EXPERT and L-Cysteine S-Sulfate Sodium Sesquihydrate EMPROVE EXPERT, enable high concentrations of tyrosine and cysteine in cell culture feeds. They can also be integrated into the main bioprocessing feed, simplifying fed-batch process with optimized productivity and reduced risk. The products meet industry quality and GMP (per IPEC) standards, and these amino acids derivatives are stable and soluble at neutral pH and room temperature.